Transplanting an animal organ into a human is now a closer reality following the successful xenotransplantation of a genetically modified pig liver into a patient diagnosed with brain death in China. The operation was intended to evaluate organ function over a 10-day period. This is a complex experimental trial that did not involve removing the patient's liver and still requires further study. However, the positive preclinical results suggest this strategy could save the lives of those waiting for a human organ, at least in certain cases.
Biocryst Pharmaceuticals Inc. has described kallikrein 5 (KLK5; KLK-L2) inhibitors reported to be useful for the treatment of allergy, asthma, cancer, conjunctivitis, dermatological disorders, gastrointestinal conditions, inflammatory disorders and rhinitis, among others.
West Pharmaceutical Services Inc. has divulged pyrazolopyridine-containing compounds reported to be useful as DNA-dependent protein kinase (DNA-PK) inhibitors.
Convelo Therapeutics Inc. and Genentech Inc. have identified lanosterol 14α-demethylase (CYP51A1; CYP51) inhibitors reported to be useful for the treatment of multiple sclerosis, encephalomyelitis, optic neuritis, schizophrenia, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.
Kinnate Biopharma Inc. has synthesized mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors reported to be useful for the treatment of cancer.
Arrepath Inc. has disclosed UDP-2,3-diacylglucosamine hydrolase (LpxH; bacterial) inhibitors reported to be useful for the treatment of gram-negative bacterial infections.
Age-related macular degeneration (AMD) is the leading cause of blindness among older adults. The exudative or ‘wet’ form of the disease is characterized by the growth of abnormal blood vessels from the choroid into the subretinal space, known as choroidal neovascularization (CNV), leading to macular edema.
Hepatitis B virus (HBV) infection is associated with liver diseases, including chronic hepatitis, which notably increases the risk of cirrhosis and hepatocellular carcinoma (HCC) development. Although some of the current treatment strategies promote virological suppression, they are insufficient to halt HCC development.
Dyne Therapeutics Inc. is advancing novel therapeutics for people living with genetically driven neuromuscular diseases. Representatives from the company recently presented a poster showcasing preclinical and early clinical results from the development of their proprietary FORCE platform applied to Duchenne muscular dystrophy (DMD).
Navigo Proteins GmbH has established a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, to advance the preclinical development of next-generation radiotheranostics using the Auger-electron emitting radioisotope Terbium (161Tb).
RSS
